Genomic Health (GHDX) Reports In-Line Q2 EPS

Genomic Health (NASDAQ: GHDX) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $82 million versus the consensus estimate of $81.27 million.

GUIDANCE:

Genomic Health sees FY2016 EPS of ($0.37)-($0.55), versus the consensus of ($0.45). Genomic Health sees FY2016 revenue of $325-335 million, versus prior guidance of $320-335 million and the consensus of $330.5 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
• Eaton (ETN) Tops Q2 EPS by 8c, Beats on Revenue; Offers Q3 Guidance
• Regal-Beloit (RBC) Tops Q1 EPS by 47c; offers guidance